ClinicalTrials.gg
RecruitingNCT05131022Updated Jul 2, 2026

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

A Phase 1 interventional study of NX-5948 in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) and Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Nurix Therapeutics, Inc.. Recruiting at 62 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Nurix Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
572
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States — 137 open to participants now, 252 under way, 34 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · United States.

Planned enrollment
29th of 1,298
572 · median 36
Started
2022
with 31 others
Phase 1
485 of 1,501
26 open now
Primary completion
2027-01
later than 85 of 248 live
Registered
1,352nd of 1,501
by date

Among the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, this one is the 29th largest by planned enrollment of the 1,298 interventional ones that give a count, is one of 32 that started in 2022, is one of 485 in phase 1, reaches primary completion later than 85 of the 248 other live ones, and was the 1,352nd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

137 of the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States are open now. Recruiting first, the newest first:

132 more — sign in →

All 137 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, or all of them as a file.
02

Study summary

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

Read the detailed description

Phase 1a is a dose escalation to evaluate the safety and tolerability of NX-5948 in adult patients with relapsed/refractory (R/R) B cell malignancies who have received at least 2 prior lines of therapy, or at least 1 prior line of therapy for Primary Central Nervous System Lymphoma (PCNSL), and for whom no other therapies are known to provide clinical benefit. Indications include: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Waldenstrom Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Primary Central Nervous System Lymphoma (PCNSL) or any of the above indications with disease in the central nervous system or Secondary Central Nervous System Lymphoma (SCNSL).

Phase 1b Part 1, called safety expansion, investigates the safety and anti-tumor activity of NX-5948 at the dose(s) selected in Phase 1a in up to 17 expansion cohorts of patients with histologically confirmed B-cell malignancy indications who have received specified prior therapies based on indication:

  • CLL or SLL (patients may be randomized to one of two dose levels investigated for CLL/SLL until an optimal dose is selected)
  • MCL
  • MZL
  • WM
  • DLBCL
  • FL
  • PCNSL/SCNSL

Phase 1b Part 2, called cohort expansion, will further investigate the anti-tumor activity of NX-5948 at the dose(s) selected in Phase 1b par 1 in one additional expansion arm of CLL/SLL patients.

03

Conditions studied

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Follicular Lymphoma (FL)
  • Mantle Cell Lymphoma (MCL)
  • Marginal Zone Lymphoma (MZL)
  • Waldenstrom Macroglobulinemia (WM)
  • Primary Central Nervous System Lymphoma (PCNSL)
  • Secondary Central Nervous System Lymphoma (SCNSL)

Keywords

  • BTK Degrader
  • BTK Inhibitor
  • B-Cell Malignancy
  • Lymphoma
  • C481
  • C481S
  • Bruton's Tyrosine Kinase
  • NX-5948
  • Targeted Protein Degradation
  • Chimeric Targeting Molecule (CTM)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age ≥18 years
  • Patients in Phase 1a (Dose Escalation) must have confirmed R/R CLL, SLL, DLBCL (subgroups include Richter-transformed DLBCL, germinal center B-cell type, activated B-cell type, high-grade B-cell lymphoma with MYC and BCL-2 and/or BCL-6 rearrangements, high-grade B-cell lymphomas NOS), FL, MCL, MZL (subtypes include EMZL, MALT, NMZL, SMZL), WM, or PCNSL.
  • Patients in Phase 1a must meet the following:

    o For non-PCNSL indications, received at least 2 and have no other available therapies known to provide clinical benefit. For PCNSL, received at least 1 prior line of therapy

  • Patients in Phase 1b (Safety and Cohort Expansion) must have 1 of the following histologically documented B-cell , must meet criteria for systemic treatment, and must have received prior therapies and/or molecular features based on details described for each cohort: CLL or SLL, DLBCL, MCL, FL, MZL, WM, or PCNSL/SCNSL.
  • per response criteria specific to the malignancy.
  • (ECOG) performance status of 0 or 1 (0-2 for patients with PCNSL and secondary CNS involvement).
  • Adequate organ and bone marrow function

Key Exclusion Criteria:

  • Known or suspected active prolymphocytic leukemia or Richter's transformation to Hodgkin's lymphoma prior to study enrollment
  • Prior treatment for the indication under study for anti-cancer intent that includes:

    1. Radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation).
    2. Prior systemic chemotherapy within 2 weeks of planned start of study drug.
    3. Prior monoclonal antibody therapy within 4 weeks of planned start of study drug, except for patients enrolling in Cohort 16 (CLL with secondary wAIHA) where a 16-week is required.
    4. Prior small molecule therapy within 2 weeks or 5 half-lives (whichever is shorter) of planned start of study drug.
    5. or allogeneic stem cell transplant within 100 days prior to planned start of study drug.
    6. Chimeric antigen receptor (CAR) T-cell therapy within 100 days prior to start of study drug (within 60 days prior to start of study drug for Phase 1b).
    7. Use of systemic outside of dosing limits described below and within 7 days prior to initiation of study treatment excepting those used as prophylaxis for radio diagnostic contrast. Patients with PCNSL/SCNSL: no greater than 40 mg/day prednisone, or equivalent. Patients with PCNSL/SCNSL using greater than 20 mg/day prednisone, or equivalent, must be clinically stable at that dose for 7 days. All other diagnoses: no greater than 20 mg/day prednisone or equivalent.
    8. Use of systemic drugs other than systemic corticosteroids for any medical condition within 60 days prior to first dose of study drug
    9. Previously treated with a BTK degrader
  • Active, uncontrolled hemolytic anemia (except for patients enrolling in Cohort 16) or active, uncontrolled autoimmune thrombocytopenia.
  • Patient has any of the following within 6 months of planned start of study drug:

    1. Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, or placement of a coronary arterial stent
    2. Uncontrolled atrial fibrillation or other arrhythmias, conduction abnormalities, or (NYHA) class III or IV heart failure
    3. Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), stroke, or intracranial hemorrhage
    4. Any other significant cardiac condition (e.g., pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, severe congenital heart disease, or persistent uncontrolled hypertension defined as systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg despite optimal medical management)
  • Bleeding diathesis, or other known risk for acute blood loss.
  • History of Grade ≥ 2 hemorrhage within 28 days of planned start of study drug.
  • Active known concurrent malignancy or malignancy other than the one under study within the past 3 years. (Exceptions include, but are not limited to, patients with more recent history of basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast may enroll if they have undergone curative therapy and have no evidence of disease).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
572 participants (estimated)

Study arms

  • Experimental
    Phase 1a Dose Escalation

    Multiple dose levels of NX-5948 to be evaluated; determination of Maximum Tolerated Dose/Phase 1b recommended dose(s)

    Drug: NX-5948

  • Experimental
    Phase 1b Part 1 Cohort 1 in CLL or SLL with prior BTKi and BCL2i

    CLL or SLL with prior exposure to both a Bruton's tyrosine kinase inhibitor (BTKi) and BCL-2 inhibitor, unless previously deemed ineligible for a BCL-2i. Patients enrolled in CLL/SLL arm will be randomized to one of two dose levels.

    Drug: NX-5948

  • Experimental
    Phase 1b Part 1 Cohort 2 in CLL/SLL with non-C481S BTK mutations

    Prior exposure to both BTKi and BCL-2i (unless deemed ineligible for BCL-2i by Investigator at the time of study enrollment) and documented BTK mutation other than C481S within 6 months prior to study entry

    Drug: NX-5948

  • Experimental
    Phase 1b Part 1 Cohort 3 in CLL/SLL with prior non-covalent BTKi

    CLL/SLL with prior exposure to ncBTKi and are BCL-2i naïve.

    Drug: NX-5948

  • Experimental
    Phase 1b Part 1 Cohort 4 in CLL/SLL with TP53 or 17p deletion, 2L, prior BTKi

    Patients with documented TP53 mutation or 17p deletion and 1 prior line of therapy that included a BTKi and are BCL-2i naïve.

    Drug: NX-5948

  • Experimental
    Phase 1b Part 1 Cohort 5 in CLL/SLL with 2L+, prior BTKi

    Patients with at least 1 prior line of therapy that included a BTKi and are BCL-2i naïve.

    Drug: NX-5948

  • Experimental
    Phase 1b Part 1 Cohort 6 in MCL

    Non-blastoid MCL with prior exposure to a BTKi and an anti-CD20 monoclonal antibody (mAb)-based chemoimmunotherapy regimen

    Drug: NX-5948

  • Experimental
    Phase 1b Part 1 Cohort 7 in MZL

    MZL (EMZL, MALT, NMZL, SMZL) with prior exposure to an anti-CD20 mAb-based chemo-immunotherapy regimen and an additional line of therapy

    Drug: NX-5948

  • Experimental
    Phase 1b Part 1 Cohort 8 in WM (3L+)

    WM with prior exposure to a BTKi and at least an additional line of therapy

    Drug: NX-5948

  • Experimental
    Phase 1b Part 1 Cohort 9 in WM (2L)

    WM following upfront therapy with a BTKi

    Drug: NX-5948

  • Experimental
    Phase 1b Part 1 Cohort 10 in DLBCL

    DLBCL which transformed from indolent lymphoma or Richters transformation with prior exposure to an anthracycline (unless previously deemed ineligible to receive), an anti-CD20 mAb-based chemoimmunotherapy regimen, and an additional line of therapy

    Drug: NX-5948

  • Experimental
    Phase 1b Part 1 Cohort 11 in FL

    FL (grade 1-3a) with prior exposure to an anti-CD20 mAb-based chemoimmunotherapy regimen and an additional line of therapy

    Drug: NX-5948

  • Experimental
    Phase 1b Part 1 Cohort 12 in PCNSL/SCNSL

    PCNSL following at least 1 prior line of therapy that included a BTKi (2L+) or following 2 or more prior lines of therapy (3L+), or SCNSL patients meeting criteria for a non-CLL/SLL cohort enrolling that disease with secondary CNS involvement of lymphoma

    Drug: NX-5948

  • Experimental
    Phase 1b Part 1 Cohort 13 in PCNSL

    PCNSL following upfront therapy and with no prior exposure to a BTKi (2L).

    Drug: NX-5948

  • Experimental
    Phase 1b Part 2 in CLL or SLL with prior BTKi and BCL-2i

    CLL or SLL with prior exposure to both a Bruton's tyrosine kinase inhibitor (BTKi) and BCL-2 inhibitor

    Drug: NX-5948

  • Experimental
    Phase 1b Part 1 Cohort 14 in first-line WM

    Treatment-naïve WM deemed unfit for chemoimmunotherapy

    Drug: NX-5948

  • Experimental
    Phase 1b Part 1 Cohort 15 in BTKi-naive CLL/SLL

    First-line (1L) or second-line+ (2L)+ CLL/SLL with no prior exposure to a BTKi

    Drug: NX-5948

  • Experimental
    Phase 1b Part 1 Cohort 16 in CLL/SLL with secondary warm autoimmune hemolytic anemia (wAIHA)

    BTKi-exposed R/R CLL or SLL with secondary wAIHA

    Drug: NX-5948

  • Experimental
    Phase 1b Part 1 Cohort 17 in CLL/SLL with CNS involvement

    BTKi-exposed R/R CLL or SLL with CNS involvement

    Drug: NX-5948

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with protocol specified dose-limiting toxicities

    Phase 1a

    Time frame: Up to 24 months

  2. To establish the maximum tolerated dose and/or recommended Phase 1b dose(s)

    Phase 1a

    Time frame: Up to 24 months

  3. To evaluate the anti-tumor activity of NX-5948 in the dose levels selected for Phase 1b safety expansion based on overall response rate (ORR) as assessed by Investigator

    Phase 1b Part 1

    Time frame: Up to 3 years

  4. Number of participants with treatment-emergent adverse events (TEAEs); Grade 3, 4, 5 TEAEs, serious adverse events (SAEs), TEAEs leading to study drug discontinuation, deaths due to TEAEs, and all deaths

    Phase 1a / Phase 1b Part 1

    Time frame: Up to 6 years

  5. To further evaluate the anti-tumor activity of NX-5948 in patients with CLL/SLL at the dose identified in Phase 1b Part 1 based on overall response rate (ORR) as assessed by Investigator

    Phase 1b Part 2

    Time frame: Up to 3 years

Secondary outcomes

  1. Pharmacokinetic (PK) profile of NX-5948: Maximum Serum Concentration

    Phase 1a / Phase 1b Part 1 and Part 2 - Sampling following the first dose, pre- and post-dose at selected cycles and at the end of treatment

    Time frame: Up to 6 years

  2. Pharmacodynamic (PD) profile of NX-5948: Changes from baseline of BTK levels in B-cells

    Phase 1a / Phase 1b Part 1 and Part 2 - Sampling at screening, following the first dose, pre and post-dose at selected cycles and at the end of treatment

    Time frame: Up to 6 years

  3. Complete response (CR) rate / CR with incomplete marrow recovery as assessed by the Investigator

    Phase 1a / Phase 1b Part 1 and Part 2

    Time frame: Up to 6 years

  4. Duration of response (DOR) as assessed by the Investigator

    Phase 1a / Phase 1b Part 1 and Part 2

    Time frame: Up to 6 years

  5. Progression-free survival (PFS) as assessed by the Investigator

    Phase 1a / Phase 1b Part 1 and Part 2

    Time frame: Up to 6 years

  6. Time to next therapy

    Phase 1a / Phase 1b Part 1 and Part 2

    Time frame: Up to 6 years

  7. Number of participants with treatment-emergent adverse events (TEAEs); Grade 3, 4, 5 TEAEs, serious adverse events (SAEs), TEAEs leading to study drug discontinuation, deaths due to TEAEs, and all deaths

    Phase 1b Part 2

    Time frame: Up to 3 years

07

Study locations

53 of 62 sites recruiting
08

References and documents

Publications

  • Zhang D, Harris HM, Chen J, Judy J, James G, Kelly A, McIntosh J, Tenn-McClellan A, Ambing E, Tan YS, Lu H, Gajewski S, Clifton MC, Yung S, Robbins DW, Pirooznia M, Skanland SS, Gaglione E, Mhibik M, Underbayev C, Ahn IE, Sun C, Herman SEM, Noviski M, Wiestner A. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts. Blood. 2023 Mar 30;141(13):1584-1596. doi: 10.1182/blood.2022016934. PubMed 36375120 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Jan 2027, 57 months after the start.

Of 84 industry-sponsored phase 1 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's planned 57 months is close to that.

Counting every sponsor, half of 180 studies reached it within 56 months; a quarter within 39 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2021
First posted
Nov 23, 2021
StartActual
Apr 13, 2022
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2028
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05131022
Lead sponsor
Nurix Therapeutics, Inc.
Responsible party
Sponsor
First posted
Nov 23, 2021
Start date
Apr 13, 2022
Primary completion
Jan 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jul 2, 2026

Study contacts

Additional Site Contact Information
Contact
clinicaltrials@nurixtx.com
+1 (415) 417-3418
Study Director
study director · Nurix Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NX-5948

Start the discussion